Cargando…
A five-factor biomarker profile obtained week 4–12 of treatment for improved prognostication in metastatic renal cell carcinoma: Results from DARENCA study 2
Background: Several biomarkers of treatment efficacy have been associated with a better prognosis in patients with metastatic renal cell carcinoma (mRCC). The prognostic significance of biomarkers in the early treatment phase is unclear. Material and methods: In a complete national cohort of mRCC pa...
Autores principales: | Soerensen, Anne V., Geertsen, Poul F., Christensen, Ib J., Hermann, Gregers G., Jensen, Niels V., Fode, Kirsten, Petersen, Astrid, Sandin, Rickard, Donskov, Frede |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4819832/ https://www.ncbi.nlm.nih.gov/pubmed/26449266 http://dx.doi.org/10.3109/0284186X.2015.1091499 |
Ejemplares similares
-
Registrations of Patients with Renal Cell Carcinoma in the Nationwide Danish Renal Cancer Database versus the Danish Cancer Registry: Data Quality, Completeness and Survival (DaRenCa Study-3)
por: Danckert, Bolette, et al.
Publicado: (2020) -
Fatigue, quality of life and metabolic changes in men treated with first-line enzalutamide versus abiraterone plus prednisolone for metastatic castration-resistant prostate cancer (HEAT): a randomised trial protocol
por: Kvorning Ternov, Klara, et al.
Publicado: (2019) -
The Effect of Radiotherapy on the Concentration of Plasma Lipids in Elderly Prostate Cancer Patients
por: Wolny-Rokicka, Edyta, et al.
Publicado: (2019) -
Renal Cell Carcinoma With Extensive Tumor Thrombus Into the Inferior Vena Cava and Right Atrium in a 70-Year-Old Man
por: Oltean, Monica-Alexandra, et al.
Publicado: (2019) -
Exploring Prostate Cancer Patients’ Interest and Preferences for Receiving Genetic Risk Information About Cancer Aggressiveness
por: Roy, Siddhartha, et al.
Publicado: (2020)